MedTrace Logo

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-01

No results posted yet for this study

Summary

This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain anti-psychotic medications (Risperdal, Seroquel, and/or Zyprexa).

Conditions

Interventions

DIETARY_SUPPLEMENT

IHBG-10

500 mg IHBG-10

DIETARY_SUPPLEMENT

Placebo

Placebo taken 15 minutes prior to the three main meals of the day

Sponsors & Collaborators

  • Avera McKennan Hospital & University Health Center

    lead OTHER

Principal Investigators

  • Timothy Soundy, MD · Avera McKennan Hospital & University Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272752 on ClinicalTrials.gov